drugset / Trial / NCT02170376
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg entacapone (ENT).
Timeline
- Start
- 2011-09
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entacapone | Small molecule | 200 mg | — |
| Subject | Levodopa/carbidopa | Unknown | — | — |
| Subject | Opicapone | Small molecule | 25 mg | — |
| Subject | Opicapone | Small molecule | 50 mg | — |
| Subject | Opicapone | Small molecule | 75 mg | — |